Novartis Agrees to Pay $245 Million to Resolve Antitrust Litigation

Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.

The settlements with so-called direct purchasers, indirect purchasers and retailers require approval by a federal judge in Manhattan, and will resolve all outstanding claims against the company over the matter, Novartis said.

CVS Health Corp, Kroger Co, Rite Aid Corp and Walgreens Boots Alliance Inc are among the plaintiffs in the civil litigation, which began in 2018.

Read the source article at finance.yahoo.com